Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clgc.2019.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exhalation of Rn-219 by patients treated with Radium-223.
EJNMMI Phys
January 2025
Department for Radiation Protection and Medical Physics, Hannover Medical School, Carl-Neuberg- Str. 1, 30625, Hannover, Germany.
Background: Treatment with Ra-223 dichloride is approved for the therapy of castration resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastases in Europe since 2013, and Ra-223 is under discussion for labelling other molecules and nanoparticles. The direct progeny of Ra-223 is Rn-219, also known as actinon, a radioactive noble gas with a half-life of 3.98 s.
View Article and Find Full Text PDFClinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer.
Curr Oncol
October 2024
Verspeeten Family Cancer Centre, Victoria Hospital, London Health Sciences Centre, London, ON N6A 5W9, Canada.
Radium-223 dichloride (radium-223) is a bone-targeting radioisotope therapy that aids in the survival of patients with metastatic castration-resistant prostate cancer (mCRPC) to bones. This study aimed to describe the clinical characteristics and outcomes of patients with mCRPC treated with radium-223 in a real-world setting. This was a retrospective study of patients with mCRPC treated with radium-223 between 2016 and 2020 at the London Health Sciences Centre in London, Canada.
View Article and Find Full Text PDFTreatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Front Med (Lausanne)
October 2024
Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Several life-prolonging therapies with diverse mechanisms of action (MoA) are available for the treatment of metastatic hormone-sensitive/castration-resistant prostate cancer, with many patients requiring multiple lines of therapy. Nevertheless, treatment optimization to further delay disease progression and improve overall survival remains an unmet need. Despite the number of agents with differing MoAs approved for advanced prostate cancer, many patients receive only one or two life-prolonging therapies.
View Article and Find Full Text PDFEvaluating response to radium-223 using Ga-PSMA PET/CT imaging in patients with metastatic castration-resistant prostate cancer.
Ann Nucl Med
October 2024
Department of Nuclear Medicine, Institut Jules Bordet, Hopital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Rue Meylemeersch 90, 1070, Brussels, Belgium.
Article Synopsis
- The study examined the effectiveness of PSMA PET/CT imaging in tracking patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing Radium-223 treatment, as traditional methods like PSA values are not reliable for follow-up.
- A total of 28 patients were analyzed, finding that a significant portion showed disease progression using two different imaging criteria, with patients experiencing progression having a higher risk of death compared to those without progression.
- The findings suggest that PSMA PET/CT is a useful tool for monitoring treatment response in mCRPC patients, with both imaging criteria yielding similar predictive outcomes for overall survival after treatment.
Predictive and Prognostic F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with Ra.
Cancers (Basel)
July 2024
Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain.
Purpose: We aimed to develop a nomogram able to predict treatment failure, skeletal events, and overall survival (OS) in patients with castration-resistant prostate cancer with bone metastases (CRPC-BM) treated with Radium-223 dichloride (Ra).
Patients And Methods: Patients from the Castilla-La Mancha Spanish region were prospectively included in the ChoPET-Rad multicenter study from January 2015 to December 2022. Patients underwent baseline, interim, and end-of-treatment bone scintigraphy (BS) and F-Fluorocholine PET/CT (FCH PET/CT) scans, obtaining multiple imaging radiomics as well as clinical and biochemical variables during follow-up and studying their association with the previously defined end-points.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!